Garzulys (insulin aspart-fsan)

Where it stands

Garzulys (insulin aspart-fsan) was approved by the US FDA on 2026-07-24. The sponsor is Emerge Bioscience Pte. Ltd., and the application is BLA761497. The records list the status as Approved and the product as a biosimilar.

The records show two presentations, a pen and a vial. They do not give the therapeutic area or the approved indication, so this analysis cannot describe the labeled use, patient population or dosing. The approval is the only milestone on record. The CHMP opinion date is blank, which is consistent with a US-only record. No EU filing or opinion is documented.

Regulatory pathway and designations

The only designation on record is Biosimilar. In the US, a biosimilar is a biological product approved under a BLA that relies on a demonstration of high similarity to an FDA-licensed reference product, with no clinically meaningful differences in safety, purity or potency. The BLA number is consistent with that biologics pathway. The records do not name the reference product, so it should be confirmed from the FDA label or the Purple Book.

The nonproprietary name carries the suffix "-fsan". Under FDA naming convention for biological products, a distinguishing four-letter suffix is attached to the core name. This helps tell products apart in prescribing and in adverse-event reporting.

The records do not say whether Garzulys has an interchangeability designation. Interchangeability is a separate FDA determination that bears on pharmacy-level substitution, and it should not be assumed from the biosimilar status alone. The records also give no information on review timelines, advisory committee activity, or orphan or expedited designations.

Safety and pharmacovigilance

The records contain no safety data. They include no label warnings, no postmarketing requirements or commitments, and no risk management program details. Nothing here supports any statement about the product's safety profile or any product-specific risk.

As general context, approved biologics, including biosimilars, are monitored through routine postmarketing pharmacovigilance. This includes spontaneous adverse-event reporting to FDA and sponsor safety reporting. The distinguishing suffix aids attribution of reports to a specific product. For an insulin product, a reviewer would normally check the label for class-level considerations such as hypoglycemia and immunogenicity. Those points have to be verified in the approved prescribing information, which is not part of these records.

What to watch

The first step is to obtain the approval letter and prescribing information to confirm the reference product, the indication, the strengths and presentations, and any interchangeability status. The records leave all of these blank.

Commercial and operational points are not covered by the records and should be checked separately. These include launch timing, supply and device availability for the pen and vial, and any patent or exclusivity issues. Also look for further regulatory activity, such as ex-US submissions or label updates, and for any postmarketing safety communications after launch.